石药(01093.HK)两款丁苯(酉太)产品明年3月底价下降逾五成
石药集团(01093.HK)公布,已就丁苯(酉太)软胶囊及丁苯(酉太)氯化钠注射液的医保支付标准参与国家医保局谈判,两款产品新医保支付标准分别定为每粒3.36元人民币(下同)及每支139元,较目前的全国最低售价分别降低55.6%及51.3%,新定价於2021年3月1日起生效。
公司表示,该等产品的全国售价将会相应调整至新医保支付标准的水平,预期售价下调会在一定时期内对该等产品的未来收入带来下降压力,但同时亦会提高产品的可负担性,料刺激需求,带动销量增长,一定程度上弥补价格下降对收入的影响。石药表示,本次医保谈判完成亦可能会加快该等产品的医院准入,并化解其被列入国家和各省市集中带量采购的风险,现阶段尚不确定医保支付标准调整对集团可能产生的影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.